GU Cancers 2024 | TALAPRO-2: exploratory analyses of HRR gene subgroups in mCRPC

Stefanie Zschaebitz, MD, Heidelberg University Hospital, Heidelberg, Germany, discusses findings from an exploratory analyses of homologous recombination repair (HRR) gene subgroups in the Phase III TALAPRO-2 trial (NCT03395197). First-line talazoparib and enzalutamide were assessed in patients with metastatic castration-resistant prostate cancer (mCRPC), irrespective of homologous recombination repair gene alterations (HRRm). A considerable efficacy benefit was observed across various molecular subgroups, particularly in the BRCA1-PALB2-BRCA2 axis and CDK12. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.